CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 8, 2018--Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Goldman Sachs 39 th Annual Global Healthcare Conference on Tuesday, June 12, 2018 at 9:20 A.M. PT (12:20 P.M. ET) in Rancho Palos Verdes, CA.

A live webcast of the presentation can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference.

About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering CNS disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA A and NMDA. Sage's lead program, a proprietary IV formulation of brexanolone (SAGE-547), has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders. For more information, please visit www.sagerx.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180608005078/en/

CONTACT: Sage Therapeutics

Investor:

Paul Cox, 617-299-8377

paul.cox@sagerx.com

or

Media:

Maureen L. Suda, 585-355-1134

maureen.suda@sagerx.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL

SOURCE: Sage Therapeutics

Copyright Business Wire 2018.

PUB: 06/08/2018 07:00 AM/DISC: 06/08/2018 07:01 AM

http://www.businesswire.com/news/home/20180608005078/en